SCHEMBL1883807

SCHEMBL1883807

c1ccc(-c2cn(-c3ccccc3)c3ccccc23)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.58
POLB P06746 2/20 0.58
DYRK1A Q13627 2/20 0.58
CTDSP1 Q9GZU7 1/20 0.58
HTR6 P50406 2/20 0.53
PTGER1 P34995 1/20 0.50
HSD17B10 Q99714 1/20 0.47
HPGD P15428 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
NR4A2 P43354 1/20 0.46
HTR7 P34969 1/20 0.46
NPSR1 Q6W5P4 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
GSK3B P49841 1/20 0.44
KCNH2 Q12809 1/20 0.44
ATM Q13315 1/20 0.43
BRD4 O60885 1/20 0.43
ESR1 P03372 1/20 0.43
ESRRA P11474 1/20 0.43
ESR2 Q92731 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13335069 0.94 KDM4E (0.57) KDM4EPOLBDYRK1ACTDSP1HTR6
SCHEMBL13335074 0.91 KDM4E (0.54) KDM4EPOLBDYRK1ACTDSP1HTR6
SCHEMBL13335089 0.90 KDM4E (0.57) KDM4EPOLBDYRK1ACTDSP1HTR6
SCHEMBL12177017 0.90 KDM4E (0.64) KDM4EPOLBDYRK1ACTDSP1HPGD
SCHEMBL13335075 0.89 KDM4E (0.53) KDM4EPOLBDYRK1ACTDSP1HTR6
SCHEMBL13335116 0.89 KDM4E (0.55) KDM4EPOLBDYRK1ACTDSP1HTR6
SCHEMBL6161254 0.88 DYRK1A (0.77) KDM4EPOLBDYRK1ACTDSP1HTR6
SCHEMBL9889080 0.88 KDM4E (0.55) KDM4EPOLBDYRK1ACTDSP1HTR6
SCHEMBL13335135 0.88 KDM4E (0.51) KDM4EPOLBDYRK1ACTDSP1HTR6
SCHEMBL10325497 0.88 KDM4E (0.51) KDM4EPOLBDYRK1ACTDSP1HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102850255-A Preparation method of 5-alkyl-2,3-diphenylindole TIANJIN DERCHEMIST SCI TECH CO LTD 2013-01-02 CN claimed
CN-102838524-A Method for preparing 5-halogen-2, 3-diphenylindole TIANJIN DERCHEMIST SCI TECH CO LTD 2012-12-26 CN claimed
US-20240383894-A1 HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME UNIV RUTGERS (US) 2024-11-21 US disclosed
EP-4452488-A1 HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME Rutgers, The State University Of New Jersey (US) 2024-10-30 EP disclosed
WO-2023122078-A1 HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2023-06-29 WO disclosed
EP-1666440-B1 METHOD FOR PRODUCING AROMATIC UNSATURATED COMPOUND SUMITOMO CHEMICAL CO (JP) 2014-01-22 EP disclosed
US-7939674-B2 Process for producing an aromatic unsaturated compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-10 US disclosed
US-7700642-B2 Process for producing an aromatic unsaturated compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-20 US disclosed
US-20090111999-A1 PROCESS FOR PRODUCING AN AROMATIC UNSATURATED COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-04-30 US disclosed
US-20080221337-A1 Process for Producing an Aromatic Unsaturated Compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-09-11 US disclosed
CN-100404479-C Method for producing aromatic unsaturated compound SUMITOMO CHEMICAL CO (JP) 2008-07-23 CN disclosed
CN-1871188-A Method for producing aromatic unsaturated compound SUMITOMO CHEMICAL CO (JP) 2006-11-29 CN disclosed
EP-1666440-A1 METHOD FOR PRODUCING AROMATIC UNSATURATED COMPOUND Sumitomo Chemical Company, Limited (JP) 2006-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221337-A1 Process for Producing an Aromatic Unsaturated Compound AHR, AR, ARSA KDM4E 2114/4885POLB 2861/4885DYRK1A 4072/4885
US-20240383894-A1 HETEROBIDENTATE IMIDAZO[1,5-A]PYRIDINE AND IMIDAZO[1,5-A]QUINOLINE N-HETEROCYCLIC CARBENE (NHC) LIGANDS, CATALYST COMPLEXES THEREOF, AND METHODS USING SAME NDC1, NUDC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 KDM4E 3055/4885POLB 1411/4885DYRK1A 1179/4885
US-20090111999-A1 PROCESS FOR PRODUCING AN AROMATIC UNSATURATED COMPOUND AHR, AR, ARSA KDM4E 2114/4885POLB 2861/4885DYRK1A 4072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.